ProMetic Life Sciences (PLI) Stock Price Up 5.3%

Shares of ProMetic Life Sciences Inc. (TSE:PLI) rose 5.3% during trading on Friday . The stock traded as high as C$1.65 and last traded at C$1.59. Approximately 1,226,966 shares changed hands during trading, a decline of 29% from the average daily volume of 1,729,067 shares. The stock had previously closed at C$1.51.

PLI has been the topic of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of ProMetic Life Sciences in a research report on Monday, November 20th. National Bank Financial decreased their price objective on shares of ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 15th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. ProMetic Life Sciences has an average rating of “Buy” and an average target price of C$3.50.

The firm has a market cap of $1,110.00, a PE ratio of -9.18 and a beta of 2.39.

TRADEMARK VIOLATION WARNING: “ProMetic Life Sciences (PLI) Stock Price Up 5.3%” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit